for Japanese

Access Committee

The Access Committee proactively promotes public-private dialogues in order to achieve appropriate evaluation of the value of innovation and to improve Japanese patients’ access to drugs, such as 14-day limited prescription of new drugs, by investigating a cost effectiveness appraisal system that is aligned with the Japanese drug pricing system and by introducing overseas examples.